Study of BHV-1300 in Graves' Disease

Biohaven

Status and phase: Enrolling; Phase 1

Conditions: Graves Disease

Treatments: Drug: BHV-1300

Study type: Interventional

Funder types: Industry

Identifiers

NCT06980649

BHV1300-202

Details and patient eligibility

About

The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.

Enrollment: 15 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

1. Participants must have serologically confirmed Graves' Disease.

Key Exclusion Criteria:

1. History of hyperthyroidism not caused by Graves' Disease (e.g., toxic adenoma or toxic multinodular goiter) and/or history of thyroid storm within six weeks of the Baseline visit.
2. History of treatment with radioactive iodine or thyroid surgery.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

15 participants in 1 patient group

BHV-1300

Experimental group

Treatment:

Drug: BHV-1300